Aligning Treatment Intensity with Access and Visit Burden

This segment examines how geography, clinic access, and visit burden shape real‑world treatment choices, even when patients express a desire for “the most aggressive” option. The discussants describe caring for patients who travel many hours each way to the cancer center and how this constrains feasible visit schedules. They explore practical flexibility, such as spacing clinic visits slightly beyond four weeks in selected cases, while clearly explaining the trade‑offs and data gaps to patients. The conversation reinforces that regimen selection must reflect not only biology and trial evidence, but also logistical realities that affect adherence and quality of life. Subcutaneous amivantamab is highlighted as an important tool to reduce time in clinic and avoid ports, making intensive regimens more accessible for some patients. Overall, the episode underscores the importance of meeting patients where they are and individualizing intensity and scheduling without losing sight of core efficacy goals.